Experience of olokizumab use in COVID-19 patients
- 作者: Antonov V.1,2, Ignatova G.1,2, Pribytkova O.1,2, Sleptsova S.3, Strebkova E.4,5, Khudyakova E.6, Simakov A.7,8, Rabets S.9, Tikhonova E.10,11, Kurmaeva D.12, Petrushin M.13, Mashkov A.14, Gayazova E.15, Yasheva I.16, Andreev M.17, Khinovker V.18, Karpunin A.19, Berezhanskiy B.20
-
隶属关系:
- South Ural State Medical University
- Regional Clinical Hospital №3
- Ammosov North-Eastern Federal University
- Seredavin Samara Regional Clinical Hospital
- Samara State Medical University, Samara
- . Luke of Crimea Stary Oskol District Hospital, Belgorod Region
- Pacific State Medical University
- Territorial Clinical Hospital №2
- Norilsk Inter-District Hospital №1
- Voyno-Yasenetsky Krasnoyarsk State Medical University
- Karpovich Krasnoyarsk Inter-District Clinical Emergency Hospital
- Penza Regional Clinical Tertiary Care Centre
- Tver Region Regional Clinical Hospital
- Voronovskoye Moscow Clinical Center for Infectious Diseases
- Nizhny Novgorod Region City Clinical Hospital №3 (Nizhny Novgorod Geriatric Center)
- Temporary Infectious Diseases Hospital for Coronavirus Disease based at the Cherkess City Clinical Hospital
- Republican Tuberculosis Dispensary
- Siberian Clinical Research Center
- Regional Clinical Hospital
- R-Pharm JSC
- 期: 卷 92, 编号 12 (2020)
- 页面: 148-154
- 栏目: Articles
- URL: https://journals.rcsi.science/0040-3660/article/view/60284
- DOI: https://doi.org/10.26442/00403660.2020.12.200522
- ID: 60284
如何引用文章
全文:
详细
Most subjects with the COVID-19 experience mild to moderate symptoms, but approximately 10% of cases suffer from severe course of disease. IL-6 inhibitors are actively used to neutralize and prevent the «cytokine storm». Olokizumab is a humanized monoclonal antibody belonging to the G4/Kappa immunoglobulin isotype that selectively binds to human IL-6 and effectively neutralizes it.
Aim. To evaluate the efficacy and safety of Artlegia (olokizumab) for the treatment of subjects with a disease caused by the SARS-COV-2 virus in a real-world clinical setting.
Materials and methods. The analysis included data of 610 subjects aged 55.08±12.68 years who received olokizumab at a single dose of 160 mg/mL – 0.4 mL subcutaneously as a preemptive anti-inflammatory therapy. The comparison group included 511 subjects aged 55.23±11.23 years who received standard therapy without IL-6 inhibitors. Control Endpoints: 1. Positive clinical changes on Day 7. 2. Changes in the CRP levels on Days 1, 2, and 7. 3. Duration of oxygen therapy. 4. Number of days in hospital. 5. Number of adverse events. 6. Disease outcome.
Results. If a «cytokine storm» occurs, immune regulatory events will trigger the development of either a protective immune response or an exacerbated inflammatory response. The use of preemptive anti-inflammatory therapy has both a short-term and, most importantly, a long-term effect on the T and B parts of the immune process. These aspects definitely require further research and observation.
Conclusion. The use of olokizumab to treat the new COVID-19 coronavirus disease has demonstrated a positive effect on clinical and laboratory parameters. Primarily, it affects the severity of clinical parameters by improving the general condition already on the first day of observation, and decreasing body temperature to normal values. The changes in the C-reactive protein levels show a significant effect of the IL-6 inhibitor on the systemic inflammatory response.
作者简介
V. Antonov
South Ural State Medical University; Regional Clinical Hospital №3
编辑信件的主要联系方式.
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-3531-3491
д.м.н., проф. каф.
俄罗斯联邦, ChelyabinskG. Ignatova
South Ural State Medical University; Regional Clinical Hospital №3
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0877-6554
д.м.н., проф., зав. каф
俄罗斯联邦, ChelyabinskO. Pribytkova
South Ural State Medical University; Regional Clinical Hospital №3
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0818-9237
к.м.н., зав. отд-нием, гл. внештатный специалист
俄罗斯联邦, ChelyabinskS. Sleptsova
Ammosov North-Eastern Federal University
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0103-4750
д.м.н., доц., зав. каф
俄罗斯联邦, YakutskE. Strebkova
Seredavin Samara Regional Clinical Hospital; Samara State Medical University, Samara
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-0854-2264
к.м.н., доц., зав. отд-нием, внештатный специалист
俄罗斯联邦, SamaraE. Khudyakova
. Luke of Crimea Stary Oskol District Hospital, Belgorod Region
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-4408-1581
зав. отд-нием
俄罗斯联邦, Stary OskolA. Simakov
Pacific State Medical University; Territorial Clinical Hospital №2
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-3334-4673
д.м.н., доц., зав. каф. внештатный специалист
俄罗斯联邦, VladivostokS. Rabets
Norilsk Inter-District Hospital №1
Email: ant-vn@yandex.ru
ORCID iD: 0000-0003-4853-4127
зам. глав. врача, клинический фармаколог
俄罗斯联邦, NorilskE. Tikhonova
Voyno-Yasenetsky Krasnoyarsk State Medical University; Karpovich Krasnoyarsk Inter-District Clinical Emergency Hospital
Email: ant-vn@yandex.ru
ORCID iD: 0000-0001-6466-9609
д.м.н., проф., зав. каф
俄罗斯联邦, KrasnoyarskD. Kurmaeva
Penza Regional Clinical Tertiary Care Centre
Email: ant-vn@yandex.ru
ORCID iD: 0000-0001-7989-7647
к.м.н., зам. глав. врача
俄罗斯联邦, PenzaM. Petrushin
Tver Region Regional Clinical Hospital
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-2780-5138
зав. отд-нием
俄罗斯联邦, TverA. Mashkov
Voronovskoye Moscow Clinical Center for Infectious Diseases
Email: ant-vn@yandex.ru
ORCID iD: 0000-0003-3465-8372
зав. отд-нием
俄罗斯联邦, MoscowE. Gayazova
Nizhny Novgorod Region City Clinical Hospital №3 (Nizhny Novgorod Geriatric Center)
Email: ant-vn@yandex.ru
ORCID iD: 0000-0001-9621-3550
врач-невролог
俄罗斯联邦, Nizhny NovgorodI. Yasheva
Temporary Infectious Diseases Hospital for Coronavirus Disease based at the Cherkess City Clinical Hospital
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-2228-5137
зав. отд-нием
俄罗斯联邦, CherkesskM. Andreev
Republican Tuberculosis Dispensary
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-4548-2598
зам. глав. врача
俄罗斯联邦, CheboksaryV. Khinovker
Siberian Clinical Research Center
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-3162-6298
к.м.н., зав. отд-нием
俄罗斯联邦, KrasnoyarskA. Karpunin
Regional Clinical Hospital
Email: ant-vn@yandex.ru
ORCID iD: 0000-0003-0837-8895
к.м.н., глав. врач
俄罗斯联邦, RyazanB. Berezhanskiy
R-Pharm JSC
Email: ant-vn@yandex.ru
ORCID iD: 0000-0002-2551-9584
к.м.н., ст. мед. советник
俄罗斯联邦, Moscow参考
- García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol. 2020;11:1441. doi: 10.3389/fimmu.2020.01441
- Pascarella G, Strumia A, Piliego Ch, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192-206. doi: 10.1111/joim.13091
- Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446
- Mahmudpour M, Roozbeh J, Keshavarz M, et al. Cytokine. 2020;133:155151. doi: 10.1016/j.cyto.2020.155151
- Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564-81. doi: 10.1111/all.14364
- Shaw S, Bourne T, Meier C, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6(3):774-82. doi: 10.4161/mabs.28612; https://pubmed.ncbi.nlm.nih.gov/24670876
- Manjili RH, Zarei M, Habibi M, Manjili MH. COVID-19 as an acute inflammatory disease. J Immunol. 2020;205:12-9. doi: 10.4049/jimmunol.2000413
- Felsenstein S, Herbert AJ, McNamara SP, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol. 2020;215:108448. doi: 10.1016/j.clim.2020.108448.
- Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92:424-32. doi: 10.1002/jmv.25685
- Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5:917-27. doi: 10.1038/nri1732
- Huang AT, Garcia-Carreras B, Hitchings TDM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704. doi: 10.1038/s41467-020-18450-4